Publications by authors named "R Venick"
The history of intestinal transplantation can be traced back to the turn of the twentieth century. Although advancements have been made, the intestine still presents a greater challenge to transplantation than does that of other solid organs, experiencing higher rates of graft rejection and lower long-term survival. Increasingly, intestinal re-transplantation (re-ITx) is seen as a viable option and is now the fourth most common indication for ITx.
View Article and Find Full Text PDFObjectives: Patients with short bowel syndrome-associated intestinal failure (SBS-IF) require long-term parenteral nutrition and/or intravenous fluids (PN/IV) to maintain fluid or nutritional balance. We report the long-term safety, efficacy, and predictors of response in pediatric patients with SBS-IF receiving teduglutide over 96 weeks.
Methods: This was a pooled, post hoc analysis of two open-label, long-term extension (LTE) studies (NCT02949362 and NCT02954458) in children with SBS-IF.
Background: Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorders (PTLD) is the most common malignancy in children after transplant; however, difficulties for early detection may worsen the prognosis.
Methods: The prospective, multicenter, study enrolled 944 children (≤21 years of age). Of these, 872 received liver, heart, kidney, intestinal, or multivisceral transplants in seven US centers between 2014 and 2019 (NCT02182986).
Article Synopsis
- This study explored the molecular mechanisms of Fontan-associated liver disease (FALD) by examining gene expression differences in liver fibrosis among patients.
- Researchers analyzed data from 106 adults with the Fontan circulation, identifying upregulated genes in those with advanced fibrosis and assessing clinical outcomes.
- Findings revealed that patients with advanced fibrosis had increased inflammation and vascular development gene activity, but these did not predict clinical outcomes like serious complications.
Real-world experience of maralixibat in Alagille syndrome: Novel findings outside of clinical trials.
J Pediatr Gastroenterol Nutr
March 2024
Objective: Maralixibat, an ileal bile acid transporter inhibitor, is the first drug approved by the U.S. Food and Drug Administration for the treatment of cholestatic pruritus in patients aged ≥3 months with Alagille syndrome (ALGS).
View Article and Find Full Text PDF